Serum PSA testing in assessing biochemical and clinical failure

[Guest guest]

For both biochemical and clinical failure endpoints, two PSA tests per year optimizes the

sensitivity and specificity. These results suggest that the lack of a

standard PSA testing frequency will influence outcomes with regard to

CaP recurrence. In particular, this can vary results secondary to how

clinical trials are designed. ....Click

on the below link for the full

story:<http://www.urotoday.com/61/browse_categories/prostate_cancer/editorial__the_importance_of_serum_prostatespecific_antigen_testing_frequency_in_assessing_biochemical_and_clinical_failure_after_prostate_cancer_treatment12312009.html>Non-doctors are welcome to browse within UroToday.combut you'll be requested to register, which you can safely do, since this professional medical site never sends spam.